申请人:Anders Marion W.
公开号:US20100168198A1
公开(公告)日:2010-07-01
The present invention is a mitochondria-targeted antioxidant prodrug useful for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. Antioxidant prodrugs of the invention are produced by modifying an antioxidant to a fatty acid so that the resulting prodrug is targeted to and activated by an enzyme of mitochondrial fatty acid beta-oxidation.
本发明是一种线粒体靶向抗氧化剂前药,用于预防或治疗与线粒体氧化还原环境变化导致的线粒体功能障碍有关的疾病或病症。该发明的抗氧化剂前药是通过将抗氧化剂改性为脂肪酸而产生的,从而使得产生的前药能够靶向并被线粒体脂肪酸β-氧化酶激活。